Fusion Pharmaceuticals Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Total revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Change in fair value of preferred share tranche right liability
Change in fair value of preferred share warrant liability
Interest income, net
Interest income
Interest expense
Other income (expense), net

Total other income (expense), net
Loss before (provision) benefit for income taxes
Income tax (provision) benefit
Net loss
Dividends paid to preferred shareholders in the form of warrants issued
Net loss attributable to common shareholders
Net loss per share attributable to common shareholders—basic and diluted
Weighted-average common shares outstanding—basic and diluted
Unrealized (loss) gain on investments
Comprehensive loss
Net loss per share -basic
Net loss per share -diluted
Weighted-average common shares outstanding-basic
Weighted-average common shares outstanding-diluted

Comments